Status:
NOT_YET_RECRUITING
Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection
Lead Sponsor:
Orthopaedic Innovation Centre
Collaborating Sponsors:
Cytophage Technologies Inc.
Ottawa Hospital Research Institute
Conditions:
Periprosthetic Joint Infection
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of a bacteriophage therapy in a patient with a methicillin-susceptible Enterococcus faecium (E. faecium) prosth...
Detailed Description
This is a single-patient study, to assess a treatment option for a case of a recurrent methicillin-susceptible E. faecium infection in a prosthetic hip joint. The patient has repeatedly failed standar...
Eligibility Criteria
Inclusion
- This N-of-1 Phage therapy is designed for one patient who meet the following conditions
- Willingness to provide signed and dated informed consent form to participate in the clinical study
- Chronic prosthetic joint infection
- History of multiple surgical and medication managements with no success
Exclusion
- below 18 years of age
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT06942624
Start Date
May 1 2025
End Date
June 1 2026
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Concordia Hospital
Winnipeg, Manitoba, Canada, R2K 3S8